Property:Results during intervention
This is a property of type Text.
C
Cruciani et al. (2009): L-Carnitine Supplementation in Patients with Advanced Cancer and Carnitine Deficiency: A Double-Blind, Placebo-Controlled Study +
Adverse events were observed in 21 out of 29 patients (hospice patients); 7 were hospitalized (intervention arm: 4 times, placebo arm: 3 times). Fifteen hospice patients and eight non-hospice patients reported adverse events, including:
Nausea/vomiting (intervention arm: 2 times); Stomach problems (intervention arm: 2 times); Increased pain (placebo arm: 2 times); Diarrhea (intervention arm: 2 times); Confusion (placebo arm: 1 time); Tinnitus (placebo arm: 1 time)
According to the authors, only one case of constipation and one case of diarrhea were associated with carnitine. +
Cruciani et al. (2012): L-Carnitine Supplementation for the Management of Fatigue in Patients With Cancer: An Eastern Cooperative Oncology Group Phase III, Randomized, Double-Blind, Placebo-Controlled Trial +
After 4 weeks: no difference between arms for pain intensity: p=0.61, disturbance due to pain: p=0.75 +
Cruciani et al. (2012): L-Carnitine Supplementation for the Management of Fatigue in Patients With Cancer: An Eastern Cooperative Oncology Group Phase III, Randomized, Double-Blind, Placebo-Controlled Trial +
After 4 weeks: no difference between arms (p=0.93) +
Cruciani et al. (2012): L-Carnitine Supplementation for the Management of Fatigue in Patients With Cancer: An Eastern Cooperative Oncology Group Phase III, Randomized, Double-Blind, Placebo-Controlled Trial +
After 4 weeks: significant difference between arms, with higher proportion of carnitine deficit in placebo arm (intervention arm: 11%, placebo arm: 33%; p≤.001) +
Cruciani et al. (2012): L-Carnitine Supplementation for the Management of Fatigue in Patients With Cancer: An Eastern Cooperative Oncology Group Phase III, Randomized, Double-Blind, Placebo-Controlled Trial +
After 4 weeks: no difference between arms (p=0.61) +
Cruciani et al. (2012): L-Carnitine Supplementation for the Management of Fatigue in Patients With Cancer: An Eastern Cooperative Oncology Group Phase III, Randomized, Double-Blind, Placebo-Controlled Trial +
From Baseline to 8 weeks: improvement in fatigue in intervention arm: Mean difference= -0.96; 95% CI: -1.32,-0.60 and placebo arm: Mean difference= -1.11; 95% CI: -1.44,-0.78; no group difference (z-transformed difference= -0.58; p=0.57) +
Cruciani et al. (2012): L-Carnitine Supplementation for the Management of Fatigue in Patients With Cancer: An Eastern Cooperative Oncology Group Phase III, Randomized, Double-Blind, Placebo-Controlled Trial +
After 4 and 8 weeks: no difference between arms (p=0.13, p=0.63) +
Cruciani et al. (2012): L-Carnitine Supplementation for the Management of Fatigue in Patients With Cancer: An Eastern Cooperative Oncology Group Phase III, Randomized, Double-Blind, Placebo-Controlled Trial +
No difference between arms for grade 5 side effect (Fisher's exact p=0.64) +
Côté et al. (2016): Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial +
Over the course of the intervention and after: no differences for mood (p=0.3214) and sleep quality (p=0.4438) between arms +
Côté et al. (2016): Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial +
Over the course of the intervention and after: no differences for pain (p=0.6048), analgesic use (p=0.6671), no delay in time to 20% pain increase (p=0.4614) between arms +
Côté et al. (2016): Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial +
No difference between arms (p=0.4270), even after controlling for tumor site, treatment method and cancer stage at week 7 or the entire study period +
Côté et al. (2016): Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial +
Over the course of the intervention and after: no difference for nausea (p=0.7105) or antiemetic consumption (p=0.6124) between arms +
Côté et al. (2016): Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial +
No differences for sleepiness (p=0.3166), anxiety (p=0.9163) and xerostomia (p=0.8341) +
Côté et al. (2016): Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial +
Over the course of the intervention and after: no difference for weight fluctuations (p=0.1454) or need for a feeding tube (no p-value) between arms. +
Côté et al. (2016): Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial +
Over the course of the intervention and after: no difference (p=0.3295) between arms +
D
Da Costa et al. (2009): Effectiveness of Guarana (Paullinia cupana) for Postradiation Fatigue and Depression Results of a Pilot Double-Blind Randomized Study +
NA +
Da Costa et al. (2009): Effectiveness of Guarana (Paullinia cupana) for Postradiation Fatigue and Depression Results of a Pilot Double-Blind Randomized Study +
NA +
Dale et al. (2001): Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects +
In both arms most of the patients showed only a slight increase of frequency of stools, change in the quality of bowel habits and rectal discomfort. 31.6% of the control-arm was observed to have diarrhoea. 11.7% in the enzyme-arm showed similar symptoms. 6 patients (3 per arm) showed bloody stools, perforations and fistulae. +
Dale et al. (2001): Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects +
78.3% of the enzyme arm showed no skin reactions or faint erythema.
40.0% of the control-arm showed moderate to bright erythema or patchy moist desquamation. 15% of the control-arm showed confluent moist desquamation and pitting oedema. 5% of the enyzme-arm showed the same symptoms. 1 patient (control-arm) showed frank skinulceration. +
Dale et al. (2001): Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects +
During radiation therapy patients initially exhibited patchy vaginal mucositis which gradually progressed to confluent fibrous mucositis. 41.6% of both arms experienced mild pain. 16.6% of the control-arm exhibited patchy mucositis with serosanguineuos discharge. They also experienced moderate pain requiring the use of analgesics. 6.6% of the enzyme arm showed similar signs and symptoms. +